Cargando…

Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation

OBJECTIVE: To estimate the impact of using the Aptima messenger RNA (mRNA) high-risk human papilloma virus (HR-HPV) assay versus a DNA HR-HPV assay in a primary HPV cervical screening programme. DESIGN: One hypothetical cohort followed for 3 years through HPV primary cervical screening. SETTING: Eng...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weston, Georgie, Dombrowski, Caroline, Harvey, Michael J, Iftner, Thomas, Kyrgiou, Maria, Founta, Christina, Adams, Elisabeth J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064071/ https://www.ncbi.nlm.nih.gov/pubmed/32152154 http://dx.doi.org/10.1136/bmjopen-2019-031303

Ejemplares similares

Health economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA HR-HPV assay for the proposed French cervical screening programme
por: Dombrowski, Caroline A., et al.
Publicado: (2022)

Comparing the Cervista HPV HR Test and Hybrid Capture 2 Assay in a Dutch Screening Population: Improved Specificity of the Cervista HPV HR Test by Changing the Cut-Off
por: Boers, Aniek, et al.
Publicado: (2014)

Triage of hrHPV-positive women: comparison of two commercial methylation-specific PCR assays
por: Dippmann, Carolin, et al.
Publicado: (2020)

Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework
por: Dhillon, Sharonjit K., et al.
Publicado: (2021)

Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda
por: Sinayobye, Jean d’Amour, et al.
Publicado: (2014)

A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada
por: Weston, Georgie, et al.
Publicado: (2021)

Molecular characterization of high-risk human papillomavirus (HR-HPV) in women in Lomé, Togo
por: Kuassi-Kpede, Akouélé P., et al.
Publicado: (2021)

High-risk Human Papillomavirus (hrHPV) Prevalence and Genotype Distribution among Turkish Women
por: Gecer, Melin
Publicado: (2023)

Cytokine Release in HR-HPV(+) Women without and with Cervical Dysplasia (CIN II and III) or Carcinoma, Compared with HR-HPV([Formula: see text]) Controls
por: Bais, Aagje G., et al.
Publicado: (2007)

Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens
por: Chernesky, Max, et al.
Publicado: (2017)

Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany
por: Iftner, Thomas, et al.
Publicado: (2019)

Study-based evaluation of the Abbott RealTime High Risk HPV test in comparison to the HC2 HR HPV test in women aged ≥30 years using residual LBC ThinPrep specimens
por: Iftner, Thomas, et al.
Publicado: (2016)

Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples
por: Avian, Alice, et al.
Publicado: (2022)

Comparative study of a novel application of automated HR HPV assay and stability in a previously untested Preservative media
por: Morel, Mike E., et al.
Publicado: (2017)

Use of extended HR-HPV Genotyping in improving the Triage Strategy of 2019 ASCCP recommendations in Women with positive HR-HPV diagnosis and Simultaneous LSIL Cytology Results
por: Xue, Huifeng, et al.
Publicado: (2021)

A comparative analysis of cycle threshold (Ct) values from Cobas4800 and AmpFire HPV assay for triage of women with positive hrHPV results
por: Zhang, Yi, et al.
Publicado: (2023)

Correction: Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples
por: Avian, Alice, et al.
Publicado: (2023)

ART is key to clearing oncogenic HPV genotypes (HR-HPV) in anal mucosa of HIV-positive MSM
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

hrHPV E5 oncoprotein: immune evasion and related immunotherapies
por: de Freitas, Antonio Carlos, et al.
Publicado: (2017)

Determination and evaluation of HR-HPV genotype in different communities of Bihar, India
por: Parwez, Akhtar, et al.
Publicado: (2022)

Longitudinal analysis on the ecological dynamics of the cervicovaginal microbiome in hrHPV infection
por: Molina, Mariano A., et al.
Publicado: (2023)

Impact of HR-HPV infection on oncological outcomes in early cervical cancer
por: Su, Xiaoqiang, et al.
Publicado: (2023)

Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping
por: Kim, Moonsik, et al.
Publicado: (2022)

High-Risk Human Papillomavirus (HR-HPV) DNA Detection in Mouthwashes for Diagnosis of HPV-Driven Oropharynx Cancer and Its Curative Therapy—A Feasibility Study
por: Loermann, Gera, et al.
Publicado: (2022)

Evaluation of Aptima Zika Virus Assay
por: Ren, Ping, et al.
Publicado: (2017)

hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopy
por: Carozzi, F, et al.
Publicado: (2013)

LINE-1 and Alu Methylation in hrHPV-Associated Precancerous Cervical Samples
por: Chaiwongkot, Arkom, et al.
Publicado: (2022)

Development of high-throughput genotyping method of all 18 HR HPV based on the MALDI-TOF MS platform and compared with the Roche Cobas 4800 HPV assay using clinical specimens
por: Cai, Xushan, et al.
Publicado: (2019)

HR Public Session - English presentation
por: Purvis, James
Publicado: (2017)

HR metrics the world class way: how to enhance your status and build the business case for HR
por: Sullivan, John
Publicado: (2002)

Prevalence of High-Risk Human Papillomavirus (HR-HPV) Genotypes and Multiple Infections in Cervical Abnormalities from Northern Xinjiang, China
por: Wang, Lina, et al.
Publicado: (2016)

Distinct Patterns of Myeloid Cell Infiltration in Patients With hrHPV-Positive and hrHPV-Negative Penile Squamous Cell Carcinoma: The Importance of Assessing Myeloid Cell Densities Within the Spatial Context of the Tumor
por: Rafael, Tynisha S., et al.
Publicado: (2021)

An economical Nanopore sequencing assay for human papillomavirus (HPV) genotyping
por: Chan, Wai Sing, et al.
Publicado: (2020)

Assessing the Cervicovaginal Microbiota in the Context of hrHPV Infections: Temporal Dynamics and Therapeutic Strategies
por: Molina, Mariano A., et al.
Publicado: (2022)

Implication of high risk Human papillomavirus HR-HPV infection in prostate cancer in Indian population- A pioneering case-control analysis
por: Singh, Neha, et al.
Publicado: (2015)

Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework
por: Bhatia, Ramya, et al.
Publicado: (2023)

Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing
por: Kocken, M, et al.
Publicado: (2012)

Evaluation of 3D-CPA, HR-HPV, and TCT joint detection on cervical disease screening
por: Liang, Hui, et al.
Publicado: (2016)

Preferences and Experiences Regarding the Use of the Self-Sampling Device in hrHPV Screening for Cervical Cancer
por: Dieleman, Marjolein, et al.
Publicado: (2021)

Genotypic distribution of human papillomavirus and phylogenetic analysis of E6 and E7 gene of HR-HPV variants isolated from Pakistani population
por: Ahmed, Sameen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c7c8eimhgtbc5uo9n0j2l2qnj9